Clinical Trial Update: A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma [EARLY_Phase 1]

View source ↗

Summary

This document describes an early-phase 1 clinical trial evaluating Plixorafenib alone or with Retifanlimab in patients with BRAF-altered glioma (BRAF V600E muta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Plixorafenib (plixorafenib)
• Retifanlimab (retifanlimab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: BRAF V600E Mutation | EARLY_Phase 1 | Status: RECRUITING